Pharmacogenetics of plasma dolutegravir exposure during 1-month rifapentine/isoniazid treatment of latent tuberculosis [0.03%]
利福喷丁/异烟肼治疗潜伏性结核期间血浆多替拉韦暴露的药物基因组学研究
Nia Covington,Anne F Luetkemeyer,Marjorie Z Imperial et al.
Nia Covington et al.
In Advancing Clinical Therapeutics Globally protocol A5372, a pharmacokinetic study of dolutegravir with 1-month of daily rifapentine/isoniazid, twice-daily dolutegravir offset the induction effects of rifapentine on plasma dolutegravir tro...
Association of estrogen and progesterone receptor polymorphisms with idiopathic thin endometrium [0.03%]
雌激素受体和孕酮受体基因多态性与特发性子宫内膜薄的关系
Belén Lledo,Mónica Hortal,María Martínez et al.
Belén Lledo et al.
The research question is as follows: Are estrogen and progesterone receptor genotypes associated with thin endometrium? We performed a prospective cohort study of 129 patients who underwent preimplantation genetic testing for aneuploidies. ...
Metabolic effects of heterocyclic amines on insulin‑induced AKT phosphorylation and gluconeogenic gene expression are modified by N-acetyltransferase 2 genetic polymorphism [0.03%]
N-乙酰基转移酶2基因多态性可修饰杂环胺对胰岛素诱导的AKT磷酸化和促糖原生成基因表达的代谢效应
Kennedy M Walls,Jonathan Y Joh,Madeline M Martinez et al.
Kennedy M Walls et al.
Objective: Heterocyclic amines (HCAs) are mutagens and carcinogens primarily generated when cooking meat at high temperatures or until well-done, and their major metabolic pathway includes hepatic N-hydroxylation via CYP1...
Pharmacogenetic associations of GATA4 and KCNQ1 with ibrutinib cardiovascular toxicity [0.03%]
GATA4和KCNQ1基因多态性与伊布替尼心血管毒性的药理遗传学研究
Kelly I Nugent,Lyucheng Huang,Jai N Patel et al.
Kelly I Nugent et al.
Ibrutinib treatment is often complicated by cardiovascular side effects (CVSEs). The objective of this retrospective pharmacogenetic study is to replicate a previously reported association of 'high-risk' patients, who are homozygous carrier...
Updating probability of pathogenicity for RYR1 and CACNA1S exon variants in individuals without malignant hyperthermia after exposure to triggering anesthetics [0.03%]
触发麻醉后无恶性高热表型的RYR1和CACNA1S外显子变异体致病概率的重新评估
David A Roberts,Lisa Bastarache,Jing He et al.
David A Roberts et al.
Objectives: We aimed to classify genetic variants in RYR1 and CACNA1S associated with malignant hyperthermia using biobank genotyping data in patients exposed to triggering anesthetics without malignant hyperthermia pheno...
Updated analysis of the pharmacogenomics of pediatric bronchodilator response [0.03%]
儿童支气管扩张剂反应的药物基因组学最新分析
Jennifer Brailsford,Guillaume Labilloy,Nolan Menze et al.
Jennifer Brailsford et al.
This short communication serves as an update to previously published pilot study results on bronchodilator response (BDR) in children with asthma. We expanded our cohort from 54 to 165 pediatric patients seeking emergency department care fo...
Association of ADH1B and ALDH2 genotypes with the risk of lung adenocarcinoma [0.03%]
酒精代谢相关基因ADH1B和ALDH2多态性与肺腺癌风险的相关性分析
Tzu-Yu Pan,Jui-Ying Lee,Jia-Jen Chen et al.
Tzu-Yu Pan et al.
Objective: The incidence of lung adenocarcinoma (LAD) is increasing worldwide. Single-nucleotide polymorphisms in aldehyde dehydrogenase 2 family member gene ( ALDH2 ) rs671 and alcohol dehydrogenase 1B ( ADH1B ) rs122998...
The Pharmacogenomics Global Research Network Implementation Working Group: global collaboration to advance pharmacogenetic implementation [0.03%]
推进药物基因组学实施的药理基因组学全球研究网络实践工作组：全球协作
Larisa H Cavallari,J Kevin Hicks,Jai N Patel et al.
Larisa H Cavallari et al.
Pharmacogenetics promises to optimize treatment-related outcomes by informing optimal drug selection and dosing based on an individual's genotype in conjunction with other important clinical factors. Despite significant evidence of genetic ...
Polygenic risk score for drug-induced long QT syndrome: independent validation in a real-world patient cohort [0.03%]
多基因风险评分在药物诱发的长QT综合症中的独立验证：来自真实世界患者队列的结果
Ana I Lopez-Medina,Alessandra M Campos-Staffico,Choudhary Anwar A Chahal et al.
Ana I Lopez-Medina et al.
Objective: Drug-induced long QT syndrome (diLQTS) is an adverse reaction from over 150 FDA-approved medications, posing the risk of triggering torsades de pointes and sudden death. While common genetic variants may modest...